PMID: 9440662Jan 24, 1998Paper

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

JAMA : the Journal of the American Medical Association
S L PrestonM Corrado

Abstract

One purpose of early clinical trials is to establish the appropriate dose of an antibiotic for phase 3 trials. Development of a relationship between the ratio of drug exposure to organism minimum inhibitory concentration (MIC) and therapeutic response early in the development process would allow an optimal choice of dose to maximize response. To prospectively quantitate the relationship between plasma levels of levofloxacin and successful clinical and/or microbiological outcomes and occurrence of adverse events in infected patients. Multicenter open-label trial. Twenty-two enrolling university-affiliated medical centers. A total of 313 patients with clinical signs and symptoms of bacterial infections of the respiratory tract, skin, or urinary tract. Clinical response and microbiological eradication of pathogenic organisms. Of 313 patients, 272 had plasma concentration-time data obtained. Of these, 134 patients had a pathogen recovered from the primary infection site and had an MIC of the pathogen to levofloxacin determined. These patients constituted the primary analysis group for clinical outcome. Groups of 116 and 272 patients, respectively, were analyzed for microbiological outcome and incidence of adverse events. In a logis...Continue Reading

Citations

Dec 11, 1999·The Journal of Antimicrobial Chemotherapy·J M EntenzaP Moreillon
Dec 20, 1999·The Journal of Antimicrobial Chemotherapy·K E BowkerA P MacGowan
Nov 30, 2000·Current Infectious Disease Reports·P Ball
Nov 18, 2000·Antimicrobial Agents and Chemotherapy·J C Fung-TomcD P Bonner
Apr 17, 2001·The Annals of Pharmacotherapy·G W Amsden, K Amankwa
Mar 16, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J J SchentagJ A Paladino
Aug 29, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
Nov 21, 2001·Pharmacotherapy·B W GundersonJ C Rotschafer
Nov 17, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G L DrusanoP G Ambrose
Apr 11, 2003·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A Dalhoff, F-J Schmitz
Nov 26, 2003·Antimicrobial Agents and Chemotherapy·D Andes, W A Craig
Nov 14, 2003·The Pediatric Infectious Disease Journal·John S BradleyGeorge L Drusano
Feb 26, 2004·Drugs & Aging·Anna Maria Ferrara, Anna Maria Fietta
Mar 20, 2004·Nature Reviews. Microbiology·George L Drusano
Sep 25, 2003·Antimicrobial Agents and Chemotherapy·Federico PeaMario Furlanut
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Mario CazzolaSerafino A Marsico
Nov 26, 2003·Antimicrobial Agents and Chemotherapy·Yoshiko OtsuShigeru Kohno
May 25, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul G AmbroseRonald N Jones
Mar 16, 2005·Pharmacotherapy·John B CahillGeorge M Johnson
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·Jeffrey J CampionMartin E Evans
Jun 7, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jeffrey D Fuller, Donald E Low
Jul 1, 2006·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Marc H ScheetzCatherine M Oliphant
May 19, 2006·Drugs·Francisco Alvarez-LermaMaria-Pilar Gracia-Arnillas
Jul 17, 2007·Clinical Microbiology Reviews·John Turnidge, David L Paterson
Jul 30, 2008·Pharmaceutical Research·Tatsuo TakahashiKen-ichi Miyamoto
Jul 29, 2009·Clinical Medicine : Journal of the Royal College of Physicians of London·Roger Finch
Nov 1, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Matthew J Labreche, Christopher R Frei
Nov 5, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Takashi SuzukiYuichi Ohashi
Sep 24, 2014·Journal of Chemotherapy·Teresita Mazzei, Sara Diacciati

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.